{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:00:18Z","timestamp":1780556418097,"version":"3.54.1"},"reference-count":51,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The chemical stability of diphenhydramine (DIPH), azelastine (AZE) and bepotastine (BEPO) was examined in solutions and solids. The drugs were subjected to high temperature (70 \u00b0C for 35 h) or UV\/VIS light (18.902\u201394.510 kJ\/m2) at pH 1\u201313, to examine their percentage degradation and kinetics of degradation. Further, the stability of solid DIPH, AZE and BEPO was examined in the presence of excipients of different reactivity, i.e., citric acid (CA) and polyvinyl alcohol (PVA) under high temperature\/high humidity (70 \u00b0C\/80% RH) or UV\/VIS light (94.510 kJ\/m2). Under high temperature, DIPH degraded visibly (&gt;19%) at pH 1 and 4, AZE was shown stable, while the degradation of BEPO was rather high (&gt;17%) in all pH conditions. Under UV\/VIS irradiation all the drugs were shown labile with degradation in the range 5.5\u201396.3%. As far as the solid mixtures were concerned, all drugs interacted with excipients, especially under high temperature\/high humidity or UV\/VIS light. As a result, DIPH, AZE and BEPO were compared in terms of their stability, with regard to their different structures and acid\/base properties. All these results may be helpful for manufacturing, storing and applying these drugs in their topical (skin, nasal and ocular), oral and injectable formulations.<\/jats:p>","DOI":"10.3390\/molecules27238322","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T07:10:27Z","timestamp":1669792227000},"page":"8322","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chemical Stability Study of H1 Antihistaminic Drugs from the First and the Second Generations, Diphenhydramine, Azelastine and Bepotastine, in Pure APIs and in the Presence of Two Excipients, Citric Acid and Polyvinyl Alcohol"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2503-5272","authenticated-orcid":false,"given":"Anna","family":"Gumieniczek","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Lejwoda","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Data","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"ref_1","first-page":"145","article-title":"H1 antihistamines, current status and future directions","volume":"1","author":"Simons","year":"2008","journal-title":"WAO J."},{"key":"ref_2","first-page":"037","article-title":"Antihistamines for allergic disease: Old-aged but not old-fashioned drugs","volume":"591","author":"Ricciardi","year":"2019","journal-title":"Int. J. Allergy Medicat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5114\/aoms.2017.68534","article-title":"New antihistamines\u2014Perspectives in the treatment of some allergic and inflammatory disorders","volume":"15","author":"Tatarkiewicz","year":"2019","journal-title":"Arch. Med. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Trybus, E., Kr\u00f3l, T., and Trybus, W. (2022). The multidirectional effect of azelastine hydrochloride on cervical cancer cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23115890"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.7150\/thno.48698","article-title":"Anti-allergic drug azelastine suppresses colon tumorigenesis by directly targeting ARF1 to inhibit IQGAP1-ERK-Drp1-medictaed mitochondrial fission","volume":"11","author":"Hu","year":"2021","journal-title":"Theranostic"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"118889","DOI":"10.1016\/j.lfs.2020.118889","article-title":"Screened antihistaminic drugs inhibits SARS-CoV-2 binding with ACE2 in vitro","volume":"266","author":"Lu","year":"2021","journal-title":"Life Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"861295","DOI":"10.3389\/fphar.2022.861295","article-title":"The antihistamine azelastine identified by computational drug repurposing, inhibits infection by major variants of SARS-CoV-2 in cell cultures and reconstituted human nasal tissue","volume":"13","author":"Konrat","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_8","first-page":"111454","article-title":"Promising nanoparticulate system for topical delivery of diphenhydramine hydrochloride: In vitro and in vivo evaluation","volume":"55","author":"Aziz","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.alit.2020.04.001","article-title":"Japanese guidelines for allergic rhinitis 2020","volume":"69","author":"Okubo","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1185\/030079907X226302","article-title":"Azelastine hydrochloride: A review of pharmacology, pharmacokinetics, clinical efficacy and tolerability","volume":"23","author":"Bernstein","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"584","DOI":"10.2500\/aap.2009.30.3289","article-title":"Antihistamines treatment for allergic rhinitis: Different routes, different mechanisms?","volume":"30","year":"2009","journal-title":"Allergy Asthma Proc."},{"key":"ref_12","first-page":"1","article-title":"Evaluation of effectiveness and safety of oral bepotastine in the management of chronic urticaria","volume":"6","author":"Dhiraj","year":"2019","journal-title":"Int. J. Sci. Stud."},{"key":"ref_13","first-page":"4457","article-title":"Development of the stable, reliable, fast and simple RP-HPLC Analytical method for quantifying diphenhydramine-HCl (DPH) in pharmaceuticals","volume":"12","author":"Fayadh","year":"2020","journal-title":"Int. J. Pharm. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/sscp.201900084","article-title":"UHPLC assay and impurity methods for diphenhydramine and phenylephrine hydrochloride oral solution","volume":"3","author":"Kirkpatrick","year":"2020","journal-title":"Sep. Sci. Plus"},{"key":"ref_15","first-page":"150","article-title":"Chemical stability of diphenhydramine hydrochloride in minibags and polypropylene syrings","volume":"52","author":"Donnelly","year":"1999","journal-title":"Can. J. Hosp. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/0018578718802586","article-title":"Stability and compatibility of diphenhydramine hydrochloride in intravenous mixtures: A new look at an old drug","volume":"54","author":"Sabins","year":"2018","journal-title":"Hosp. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4914292","DOI":"10.1155\/2017\/4914292","article-title":"Application of HPTLC with densitometry for evaluation of the impact of external factors contents of diphenhydramine in its solutions","volume":"2017","author":"Bober","year":"2017","journal-title":"Int. J. Anal. Chem."},{"key":"ref_18","unstructured":"(2019). European Pharmacopoeia, Council of Europe. [10th ed.]."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.22159\/ajpcr.2018.v11i8.25506","article-title":"Stability-indicating high-performance liquid chromatography method for determination of antihistamine drug azelastine","volume":"11","author":"Patel","year":"2018","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2116\/analsci.30.691","article-title":"Stability study of the antihistamine drug azelastine HCl along with a kinetic investigation and the identification new degradation products","volume":"30","author":"Yamada","year":"2014","journal-title":"Anal. Sci."},{"key":"ref_21","first-page":"9489723","article-title":"Green analytical methods for the separation of seven antihistamines: Application in separation of azelastine and related impurities in nasal solution","volume":"2019","author":"Kassab","year":"2019","journal-title":"Int. J. Anal. Chem."},{"key":"ref_22","first-page":"135","article-title":"Stability indicating spectrophotometric and chromatographic methods for the determination of azelastine hydrochloride in presence of its alkaline degradant","volume":"14","author":"Elghobashy","year":"2014","journal-title":"Anal. Chem. Indian J."},{"key":"ref_23","first-page":"343","article-title":"Stability indicating HPLC method for the quantification of bepotastine besilate and its related substances","volume":"6","author":"Kotla","year":"2014","journal-title":"Pharm. Chem."},{"key":"ref_24","first-page":"5222","article-title":"Stability indicating chromatographic method for estimation of bepotastine besilate","volume":"5","author":"Damle","year":"2018","journal-title":"Indoam. J. Pharm. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/ajacr\/2019\/v3i130083","article-title":"Validated stability indicating HPTLC, UHPLC and UV-spectrophotometric techniques for the determination of bepotastine besilate in presence of its oxidative degrade","volume":"3","author":"Soliman","year":"2019","journal-title":"Asian J. Appl. Chem. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.xphs.2020.03.004","article-title":"Characterization of photodegradation products of bepotastine besilate and in silico evaluation of their physicochemical, absorption, distribution, metabolism, excretion and toxicity properties","volume":"109","author":"Singh","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","article-title":"Development of forced degradation and stability studies of drugs\u2014A review","volume":"4","author":"Blessy","year":"2014","journal-title":"J. Pharm. Anal."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1208\/s12249-017-0902-2","article-title":"Excipients stability; a critical aspect in stability of pharmaceuticals","volume":"19","author":"Murthy","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1007\/s11095-012-0782-9","article-title":"Impact of excipient interactions on solid dosage form stability","volume":"29","author":"Narang","year":"2012","journal-title":"Pharm. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jpha.2021.09.010","article-title":"Compatibility and stability studies involving polymers used in fused deposition modeling 3D printing of medicines","volume":"12","author":"Silva","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lambros, M., Tran, T., Fei, Q., and Nicolaou, M. (2022). Citric acid: A multifunctional pharmaceutical excipient. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14050972"},{"key":"ref_32","unstructured":"(2022, September 18). RxList. Available online: https:\/\/www.rxlist.com."},{"key":"ref_33","unstructured":"(2022, September 18). Dailymed, Available online: https:\/\/dailymed.nlm.nih.gov."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mazet, R., Jameogo, J.B.G., Wouessidjewe, D., Choisnard, L., and Geze, A. (2020). Recent advances in the design of topical ophthalmic delivery systems in the treatment of ocular surface inflammation and thei biopharmaceutical evaluation. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12060570"},{"key":"ref_35","first-page":"17","article-title":"Consequences of new approach to chemical stability tests to active pharmaceutical ingredients","volume":"7","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_36","unstructured":"Yoshioka, S., and Stella, V.J. (2002). pH and pH-Rate Profiles in Stability of Drugs and Dosage Forms, Kluwer Academic Publications."},{"key":"ref_37","unstructured":"(2022, September 18). PubChem, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/."},{"key":"ref_38","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2005). Validation of Analytical Procedures: Text and Methodology Q2(R1), ICH."},{"key":"ref_39","unstructured":"FDA Guidance for Industry (2010). Validation of Analytical Procedures: Definitions and Terminology Final Guidance."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40543-022-00317-6","article-title":"Systematic strategies for degradation kinetic study of pharmaceuticals: And issue of utmost importance concerning current stability analysis practice","volume":"13","author":"Bhangare","year":"2022","journal-title":"J. Anal. Technol."},{"key":"ref_41","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2012). ICH Guideline S10 Guidance on Photosafety Evaluation of Pharmaceuticals, ICH."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1021\/es803325j","article-title":"Indirect photodegradation of amine drugs in aqueous solution under simulated sunlight","volume":"43","author":"Chen","year":"2009","journal-title":"Environ. Sci. Technol."},{"key":"ref_43","first-page":"129","article-title":"Stability testing of pharmaceutical Products","volume":"2","author":"Bajaj","year":"2012","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/8135608","article-title":"Photostability and photostabilization of drugs and drug products","volume":"7","author":"Ahmad","year":"2016","journal-title":"Int. J. Photoenergy"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"861904","DOI":"10.1155\/2014\/861904","article-title":"Ophthalmic drug dosage firms: Characterisation and reseach methods","volume":"2014","author":"Baranowski","year":"2014","journal-title":"Sci. World J."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Be\u0107, K.B., Grabska, J., and Huck, C.W. (2020). Near-infrared spectroscopy in bioapplications. Molecules, 25.","DOI":"10.3390\/molecules25122948"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s11095-013-0994-7","article-title":"Supersolubilization and amorphization of a model basic drug haloperidol, by interaction with weak acids","volume":"30","author":"Singh","year":"2013","journal-title":"Pharm. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11095-018-2407-4","article-title":"Development of fast-dissolving amorphous solid dispersion of itraconazole by melt extrusion of its mixture with weak organic carboxylic acid and polymer","volume":"35","author":"Parikh","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_49","unstructured":"(2022, November 02). Medscape. Available online: https:\/\/medscape.com."},{"key":"ref_50","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2003). ICH Topic Q1A (R2) Stability Testing of New Drug Substances and Products, ICH."},{"key":"ref_51","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (1998). ICH Topic Q1B Photostability Testing of New Active Substances and Medicinal Products, ICH."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/23\/8322\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:29:20Z","timestamp":1760146160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/23\/8322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":51,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["molecules27238322"],"URL":"https:\/\/doi.org\/10.3390\/molecules27238322","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]}}}